VIDEO RESOURCES

Video Resources for SARCLISA

Now Playing:

Discover the IKEMA Trial: Experts Discuss Clinical Highlights

Now Playing:

Case Review: Patricia, a Patient With Gain(1q21) and Progression on 1L Maintenance

Now Playing:

Case Review: Roger, a Patient With Renal Insufficiency and Progression on 1L Maintenance

Now Playing:

Results From IKEMA: PFS, Response Rates, MRD Negativity, and Safety

Now Playing:

sarclisa Mechanism of Action

Now Playing:

Join Dr Mikhael as he discusses the latest data for SARCLISA + Kd at a median follow-up of 44 months

1L=first line; Kd=carfilzomib and dexamethasone; MOA=mechanism of action; MRD=minimal (or measurable) residual disease; PFS=progression-free survival.

Back to topTop Clinical & Access Resources